Skip to main content

GeoVax Labs, Inc. (GOVX)

NASDAQ: GOVX · IEX Real-Time Price · USD
3.87
0.05 (1.31%)
At close: Dec 8, 2021 4:00 PM
3.92
0.05 (1.29%)
After-hours:Dec 8, 2021 7:39 PM EST
Market Cap24.70M
Revenue (ttm)472,160
Net Income (ttm)-6.16M
Shares Out6.38M
EPS (ttm)-1.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume108,725
Open3.80
Previous Close3.82
Day's Range3.75 - 3.95
52-Week Range3.01 - 8.71
Beta1.88
AnalystsBuy
Price Target10.00 (+158.4%)
Earnings DateNov 11, 2021

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and...

IndustryBiotechnology
Founded2001
CEODavid Dodd
Employees7
Stock ExchangeNASDAQ
Ticker SymbolGOVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for GeoVax Labs stock is "Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
(158.40% upside)
Analyst Consensus: Buy

News

GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress

Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response

5 days ago - GlobeNewsWire

GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress

GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants such as Omicron

1 week ago - GlobeNewsWire

Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets

Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?

1 week ago - PennyStocks

GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress

GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants

3 weeks ago - GlobeNewsWire

GeoVax Shares Surge After Cancer Vaccine Patent In US

GeoVax Labs Inc (NASDAQ: GOVX) has received a U.S. patent covering its vector platform for expressing tumor-associated antigens in virus-like particles (VLPs). The platform comes from a Modified Vaccini...

3 weeks ago - Benzinga

GeoVax Labs, Inc. (NASDAQ: GOVX) Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company developing human immunotherapies and vaccines…

3 weeks ago - Stockmarketcom

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications

3 weeks ago - GlobeNewsWire

GeoVax Announces Upcoming Presentations at Scientific Conferences

ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announ...

3 weeks ago - GlobeNewsWire

GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update

Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs

3 weeks ago - GlobeNewsWire

GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate

GeoVax Labs Inc (NASDAQ: GOVX) entered into an exclusive license agreement with City of Hope, a cancer research and treatment organization, for COH04S1, a synthetic, attenuated modified vaccinia Ankara ...

4 weeks ago - Benzinga

GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope's COVID-1...

Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients

4 weeks ago - GlobeNewsWire

GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update

Conference call to be held Thursday, November 11, at 4:30 p.m. Eastern Time

1 month ago - GlobeNewsWire

GeoVax Receives Notice of Allowance for Ebola Vaccine Patent

Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation

1 month ago - GlobeNewsWire

GeoVax Stock Is Trading Higher On Gedeptin In-Licensing Pact For Solid Tumors

GeoVax Labs Inc (NASDAQ: GOVX) entered into a license agreement with PNP Therapeutics Inc to develop and commercialize Gedeptin for solid tumors.   The transaction's detailed financial terms were not di...

2 months ago - Benzinga

GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

License of Gedeptin® Adds Orphan Drug Clinical Program for  Treatment of Advanced Head and Neck Cancers

2 months ago - GlobeNewsWire

GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Atlanta, GA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today tha...

3 months ago - GlobeNewsWire

GOVX Stock: Why GeoVax Shares Are Skyrocketing Today

Geovax Labs (GOVX) stock is soaring higher on Friday after the company presented COVID-19 vaccine data at a recent conference. The post GOVX Stock: Why GeoVax Shares Are Skyrocketing Today appeared firs...

3 months ago - InvestorPlace

Why Geovax Labs Shares Are Soaring Today

Geovax Labs Inc (NASDAQ: GOVX) is trading significantly higher Friday after the company announced it presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Societ...

3 months ago - Benzinga

GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly

ATLANTA, GA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- GeoVax Vaccine Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants

3 months ago - GlobeNewsWire

GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021

ATLANTA, GA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cance...

3 months ago - GlobeNewsWire

GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update

Continued Progress on COVID-19 and Immuno-Oncology Programs

3 months ago - GlobeNewsWire

GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update

Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time

4 months ago - GlobeNewsWire

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

GeoVax Vaccine Achieves 100% Protection in a Single-Dose

4 months ago - GlobeNewsWire

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide

5 months ago - GlobeNewsWire

GeoVax to Participate in the Alliance Global Partners' Virtual Healthcare Symposium

Atlanta, GA, June 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --  GeoVax Labs, Inc . (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases a...

5 months ago - GlobeNewsWire